Keros Therapeutics (KROS) Stock Price, News & Analysis

Company Overview

Keros Therapeutics, Inc. (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company’s research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company’s lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis. KER-050 is currently being evaluated in multiple clinical trials across North America and Europe. In parallel, Keros is advancing additional preclinical programs that leverage its proprietary platform to address other hematologic and iron-related disorders.

Founded in 2019 as a spin-out from academic research, Keros Therapeutics is headquartered in Boston, Massachusetts, and collaborates with leading research institutions and clinical centers worldwide. The company’s leadership team comprises industry veterans in research and development, clinical operations and regulatory affairs, all focused on translating groundbreaking science into therapies that improve patient outcomes in serious blood diseases.

Key Stats

• Today's Range: $11.58 to $11.95
• 50-Day Range: $10.61 to $15.71
• 52-Week Range: $10.41 to $22.55
• Volume: 141,687 shs
• Average Volume: 390,977 shs
• Market Capitalization: $234.31 million
• P/E Ratio: 6.51
• Dividend Yield: N/A
• Price Target: $21.33
• Consensus Rating: Hold

Keros Therapeutics Stock Analysis - MarketRank™

Keros Therapeutics scored higher than 85% of companies evaluated by MarketBeat, and ranked 110th out of 856 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Hold

Consensus Rating

Keros Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on no strong buy ratings, 4 buy ratings, 4 hold ratings, and 1 sell rating.

Upside Potential

Keros Therapeutics has a consensus price target of $21.33, representing about 84.1% upside from its current price of $11.59.

Amount of Analyst Coverage

Keros Therapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Keros Therapeutics are expected to decrease in the coming year, from ($5.51) to ($6.21) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Keros Therapeutics is 6.40, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 38.31.

Price to Earnings Ratio vs. Sector

The P/E ratio of Keros Therapeutics is 6.40, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 29.11.

Price to Book Value per Share Ratio

Keros Therapeutics has a P/B Ratio of 0.75. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

8.94% of the float of Keros Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Keros Therapeutics has a short interest ratio ("days to cover") of 3.47, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Keros Therapeutics has recently decreased by 6.36%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Keros Therapeutics does not currently pay a dividend.

Dividend Growth

Keros Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: 0.78

News Sentiment

Keros Therapeutics has a news sentiment score of 0.78. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Keros Therapeutics this week, compared to 3 articles on an average week.

MarketBeat Follows

3 people have added Keros Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 3.6 / 5
• Insider Trading: Acquiring Shares

Net Insider Buying

Over the last three months, insiders have purchased a net $11,700.00 in company stock, which represents 0.0051% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, Keros Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $11,700.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

22.90% of the stock of Keros Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

71.56% of the stock of Keros Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

KROS Stock Analysis - Frequently Asked Questions

How have KROS shares performed this year?

Keros Therapeutics' stock was trading at $20.36 at the beginning of the year. Since then, KROS shares have decreased by 43.1% and is now trading at $11.5850.

How were Keros Therapeutics' earnings last quarter?

Keros Therapeutics, Inc. (NASDAQ:KROS) issued its quarterly earnings data on Wednesday, March, 4th. The company reported ($0.86) EPS for the quarter, missing analysts' consensus estimates of ($0.49) by $0.37. The firm's revenue was down 87.2% compared to the same quarter last year.

When did Keros Therapeutics IPO?

Keros Therapeutics (KROS) raised $90 million in an initial public offering on Wednesday, April 8th 2020. The company issued 6,000,000 shares at $14.00-$16.00 per share. Jefferies, SVB Leerink and Piper Sandler served as the underwriters for the IPO and H.C. Wainwright & Co. was co-manager.

Who are Keros Therapeutics' major shareholders?

Keros Therapeutics' top institutional shareholders include Y Intercept Hong Kong Ltd (0.83%), Principal Financial Group Inc. (0.30%), Hsbc Holdings PLC (0.27%) and Strs Ohio (0.26%). Insiders that own company stock include Carl L Gordon, Carl L Gordon, Pontifax Management 4 GP (20, Keith Regnante and Adar1 Capital Management, Llc.
View institutional ownership trends.

How do I buy shares of Keros Therapeutics?

Shares of KROS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Keros Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Keros Therapeutics investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Netflix (NFLX), Meta Platforms (META) and Home Depot (HD).

Company Calendar

• Last Earnings: 3/04/2026
• Today: 5/06/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:KROS
• CIK: 1664710
• Web: www.kerostx.com
• Phone: 617-314-6297
• Fax: N/A
• Employees: 100
• Year Founded: 2015

Price Target and Rating

• Average Price Target for Keros Therapeutics: $21.33
• High Price Target: $27.00
• Low Price Target: $16.00
• Potential Upside/Downside: +80.7%
• Consensus Rating: Hold
• Rating Score (0-4): 2.33
• Research Coverage: 9 Analysts

Profitability

• EPS (Trailing Twelve Months): $1.82
• Trailing P/E Ratio: 6.48
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $87.01 million
• Net Margins: 35.65%
• Pretax Margin: 37.65%
• Return on Equity: 14.25%
• Return on Assets: 13.27%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 15.45
• Quick Ratio: 15.45

Sales & Book Value

• Annual Sales: $244.06 million
• Price / Sales: 0.96
• Cash Flow: $4.56 per share
• Price / Cash Flow: 2.59
• Book Value: $15.51 per share
• Price / Book: 0.76

Miscellaneous

• Outstanding Shares: 19,790,000
• Free Float: 15,257,000
• Market Cap: $233.58 million
• Optionable: Optionable
• Beta: 0.95